section name header

Pronunciation

lom-i- TA-pide

Classifications

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: microsomal transfer protein inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 7% absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 99.8%.

Metabolism/Excretion: Extensively metabolized by the liver, mostly via the CYP3A4 isoenzyme; metabolites do not have lipid-lowering properties. 59.5% excreted in urine (mostly as metabolites), 33.4% in feces (mostly as parent drug).

Half-life: 39.7 hr.

Time/Action Profile

(lowering of LDL-C)

ROUTEONSETPEAKDURATION
POwithin 2 wk18 wkunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, chest pain, palpitations.

GI: liver enzymes, abdominal discomfort/pain, abdominal distention, constipation, defecation urgency, diarrhea, dyspepsia, flatulence, gastrointestinal reflux, hepatotoxicity, nausea, rectal tenesmus, vomiting, HEPATOTOXICITY.

Metab: weight.

MS: back pain.

Neuro: dizziness, headache.
Misc: fever.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Juxtapid